← Back to Search

Diagnostic Test

Nystagmus Assessment for Vertigo

N/A
Recruiting
Led By Pierre La Rochelle, MD, MSc
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
New episode of acute vertigo/dizziness/imbalance occuring during the 28 last days
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 0 to 12 weeks
Awards & highlights

Study Summary

This trial is to see if a special sign found in the eyes can help assess patients with dizziness in the emergency department.

Who is the study for?
This trial is for individuals who can consent and have experienced a new episode of acute vertigo, dizziness, or imbalance in the last 28 days. Participants must be able to speak French or English and be available for follow-up after 3 months. Those with trauma, intoxication before symptoms, or very low blood sugar levels cannot join.Check my eligibility
What is being tested?
The study tests the use of Frenzel lenses and a diagnostic algorithm to assess nystagmus (a vision condition) in patients with acute vertigo visiting the emergency department. It's designed to see if these tools are practical and accurate in a real-world setting.See study design
What are the potential side effects?
Since this trial involves diagnostic procedures rather than medications, traditional side effects like those seen with drugs are not expected. However, discomfort from wearing Frenzel lenses may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have experienced new episodes of vertigo, dizziness, or imbalance in the last 28 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 0 to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 0 to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Nystagmus detection per participant
Secondary outcome measures
Adverse Events
Emergency Department Length of stay
Initial managment self appreciation of patient presenting in the ED for an acute episode of vertigo/dizziness/imbalance
+10 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: No Frenzel Lens with Diagnostic AlgorithmExperimental Treatment1 Intervention
Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens. Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging
Group II: Frenzel Lens without Diagnostic AlgorithmExperimental Treatment1 Intervention
Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.
Group III: Frenzel Lens with Diagnostic AlgorithmExperimental Treatment2 Interventions
Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and if present describe its main characteristic. Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging
Group IV: No Frenzel Lens and No Diagnostic AlgorithmActive Control1 Intervention
The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
166 Previous Clinical Trials
106,874 Total Patients Enrolled
Pierre La Rochelle, MD, MScPrincipal InvestigatorUniversite Laval

Media Library

Diagnostic Algorithm (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT05176015 — N/A
Acquired Nystagmus Research Study Groups: Frenzel Lens with Diagnostic Algorithm, Frenzel Lens without Diagnostic Algorithm, No Frenzel Lens with Diagnostic Algorithm, No Frenzel Lens and No Diagnostic Algorithm
Acquired Nystagmus Clinical Trial 2023: Diagnostic Algorithm Highlights & Side Effects. Trial Name: NCT05176015 — N/A
Diagnostic Algorithm (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05176015 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are actively involved in this clinical experiment?

"Affirmative. The details available on clinicaltrials.gov verify that this trial is currently looking to enlist participants; the original posting was made on January 15th, 2022 with a subsequent amendment being done on February 1st, 2022. This research endeavour requires 120 volunteers from one central location."

Answered by AI

Are there any vacancies available to participate in this research?

"Affirmative. According to the clinicaltrials.gov information, this medical trial is currently open for enrollment and was first posted on January 15th 2022 with its last update being February 1st 2022. This research initiative aims to recruit 120 participants at a single site."

Answered by AI

Is the age limitation of this clinical trial limited to individuals below twenty years?

"This clinical trial is open to patients aged 18-100. There are 79 trials specifically targeting minors, while 1184 cater to individuals 65 and older."

Answered by AI

Might I be eligible to enroll in this experiment?

"120 individuals afflicted with vertigo, ranging from 18 years of age to 100 years old are being admitted into this study. To be eligible for participation, potential participants must have experienced a new episode of dizziness or imbalance within the last 7 days and demonstrate their capacity to provide consent."

Answered by AI
~16 spots leftby Jul 2024